Monday, May 23, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Infectious Diseases

The Original SARS Virus Disappeared. Here’s Why SARS-CoV-2 Will Not ‘Burn Itself Out’

by Connor Bamford
June 5, 2020
UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

A nurse tests students for COVID-19 as they arrive on the UC San Diego campus. Credit: Erik Jepsen / UC San Diego

British cancer doctor Prof Karol Sikora recently claimed that the current COVID-19 pandemic would “burn itself out”. His thinking is that if there are more infections than we realise, and that those milder, unrecorded infections result in robust immunity, then this would quickly lead to “herd immunity”, leaving the virus nowhere to go but extinct. Extend this to the world’s population and the virus eradicates itself.

But the idea that letting the virus run wild would protect us is unlikely to be valid. The antibody results coming in suggest that only a small proportion of people have been infected by SARS-CoV-2. In the UK, only an estimated 6.8% of people have had the virus; for France, the figure is just 4.4%.

This means that we are far away from achieving herd immunity. It also suggests that the virus does indeed have the relatively high fatality rate that we’ve estimated.

This raises doubts that letting the virus burn itself out would be a sensible, safe and ethical answer to the COVID-19 problem. It would be safer to imagine a future where we can live side by side with SARS-CoV-2.

Yet the virus that caused the original SARS disease – SARS-CoV-1 – no longer haunts us. What can its disappearance tell us about the likelihood of living in a world without SARS-CoV-2?

Why the Original SARS Disappeared

It was evident by early 2004 that the SARS outbreak had ended. Starting in 2002, this epidemic lasted about one and a half years, infecting at least 8,000 people and killing 10% of them. Although it mostly affected east Asian countries, by its end SARS had spread worldwide.

In the midst of the turmoil, there were fears that SARS could become a serious pandemic. The virus was passed on by respiratory transmission, had spread internationally and had the ability to cause significant disease.

In its final days, the outbreak bounced between humans and animals in wet markets across China. There would be a couple of smaller outbreaks linked to laboratory-acquired virus transmissions, but nobody would die from these.

Why did the original SARS epidemic come to end? Well, SARS-CoV-1 did not burn itself out. Rather, the outbreak was largely brought under control by simple public health measures. Testing people with symptoms (fever and respiratory problems), isolating and quarantining suspected cases, and restricting travel all had an effect.

SARS-CoV-1 was most transmissible when patients were sick, and so by isolating those with symptoms, you could effectively prevent onward spread. Nearly everybody on the planet would remain susceptible to SARS in the decades following its disappearance.

Enter COVID-19

It is clear that our response to SARS-CoV-1 led to the extinction of that lineage of viruses in humans. But we also knew that very similar viruses continued to exist in bats. It’s possible that a very closely related SARS-like virus could emerge in the not-too-distant future.

Of course, this is what happened in late 2019, when SARS-CoV-2 jumped into humans. In a few short months it had erupted into a pandemic, infecting millions of people worldwide and killing around 1% of those infected. While this new human coronavirus is distinct from the original SARS virus, it is related.

In a similar timeframe to the original SARS, SARS-CoV-2 has proved to be more contagious but seemingly less deadly than its cousin was nearly 20 years ago. An additional – and critical – concern is that SARS-CoV-2 is efficiently spread before people get sick. This makes traditional symptomatic-based public health restrictions, which worked well for SARS, largely incapable of containing COVID-19.

Challenges in Eradication

In essence, this ease of transmission means that SARS-CoV-2 is infinitely more challenging to control. We also have a poor understanding of whether catching and recovering from COVID-19 completely prevents you from catching the virus again and passing it on to others. Together, these factors mean that SARS-CoV-2 will most likely settle into the human population, becoming an endemic virus like its coronavirus cousins that are major causes of colds every winter.

While we haven’t been able to watch this “post-pandemic” scenario unfold for other human coronaviruses (although we strongly suspect this to have occurred in the not too distant past), we have ample evidence that this occurs with other viral infections. Over the last 100 years or so we have had five influenza pandemics, and descendants of the most recent pandemic influenza virus (H1N1 from 2009) continue to circulate in the population more than a decade later.

Given that we do not know how long natural immunity to COVID-19 lasts, nor whether it is capable of blocking infection completely or only symptoms, it’s not clear that SARS-CoV-2 could ever burn itself out. Therefore, our only option remains to suppress COVID-19 as much as possible until we have a safe and effective vaccine available to the masses.

ABOUT THE AUTHOR

Connor Bamford, Research Fellow, Virology, Queen’s University Belfast. Connor is a virologist with over a decade of experience in studying how the immune system defends humans and other animals against disease-causing microbes like viruses, such as the hepatitis C virus, influenza virus and Zika virus. Connor recently moved to Queen’s University Belfast as a ‘Wellcome Trust Institutional Strategic Support Fund (ISSF) Early Career Research Fellow’ to continue his research into the human immune system and antiviral proteins called ‘interferons’. Connor obtained his PhD in 2014 in molecular virology studying the mumps virus before carrying out his postdoctoral research at the MRC-University of Glasgow Centre for Virus Research (CVR) in Scotland, UK. Follow on Twitter @cggbamford

This article is courtesy of The Conversation.

Tags: CoronavirusesCOVID-19Editor PickHerd ImmunitySARSSARS-CoV-2

Related Posts

Congenital Syphilis Continues a Decade-Long Surge Across the US
Infectious Diseases

Congenital Syphilis Continues a Decade-Long Surge Across the US

April 12, 2022
Some PASC Patients May Experience Long-Lasting Airway Disease — Even if They Only Had Mild COVID-19
Infectious Diseases

Some PASC Patients May Experience Long-Lasting Airway Disease — Even if They Only Had Mild COVID-19

March 22, 2022
Neurological Symptoms are Present in Roughly Two-Thirds of Hospitalized COVID-19 Patients
Infectious Diseases

Neurological Symptoms are Present in Roughly Two-Thirds of Hospitalized COVID-19 Patients

March 21, 2022
Even Mild or Moderate COVID-19 Illness Affects Cardiovascular System in Young Adults
Infectious Diseases

Even Mild or Moderate COVID-19 Illness Affects Cardiovascular System in Young Adults

March 19, 2022
Load More

Latest News

NIH to Further Invest in Point-of-Care Technologies Research Network

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC